Report of Foreign Issuer (6-k)
27 March 2017 - 9:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March, 2017
Commission File Number
Novogen
Limited
(Translation of registrants name into English)
Level 5, 20 George Street, Hornsby, NSW 2077, Australia
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☑ Form 40-F ☐
Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note
: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note
:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☑
If
yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Novogen Limited
(Registrant)
Kate Hill
Kate Hill
Company Secretary
Date 27 March 2017
|
|
|
|
|
|
|
ASX:NRT
NASDAQ:NVGN
Novogen Ltd
(Company)
ABN 37 063 259 754
Capital Structure
Ordinary Shares on issue:
483 M
Board of Directors
Mr John OConnor
Chairman
Non-Executive Director
Mr Bryce Carmine
Deputy Chairman
Non-Executive Director
Dr James Garner
Chief Executive Officer
Managing Director
Mr Ian Phillips MNZM
Non-Executive Director
Mr Iain Ross
Non-Executive Director
Mr Steven Coffey
Non-Executive Director
|
|
MARKET RELEASE
27 March 2017
NOVOGEN RECEIVES $4.4M R&D TAX REBATE
Sydney, 27
th
March 2017 Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology-focused
biotechnology company, is pleased to confirm receipt of $4.4m from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending 30 June 2016. These funds will be utilised to support the Companys
ongoing clinical programs.
Novogen CEO, Dr James Garner said the R&D tax
rebate is an important,
non-dilutive
source of funding for Novogen. The $4.4m is in line with our expectations as reported in the Companys half yearly report, and will be allocated primarily to
progressing our clinical trials for Cantrixil and
GDC-0084.
Novogens research and development is directed towards developing meaningful new treatments for cancers where there is a high area of unmet need. The
Company has a strong pipeline of drug development assets, ranging in stage from
pre-clinical
assets to later stage programs, Cantrixil and
GDC-0084.
[ENDS]
|
|
Media and Investor Relations
Glen Zurcher
E:
glen.zurcher@irdepartment.com.au
T: +61 420 249 299
|
|
Investor Relations (US)
Robert
Kennedy
E:
robert.kennedy@novogen.com
T: +1 212 519
9832 / +1 646 662 3574
|
|
About Novogen Limited
Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an emerging oncology-focused biotechnology
company, based in Sydney, Australia. Novogen has a portfolio of four development candidates, diversified across three distinct technologies, with the potential to yield
first-in-class
and
best-in-class
agents across a range of oncology indications.
The lead program is
GDC-0084,
a small molecule
inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme. Licensed from Genentech in late 2016,
GDC-0084
is anticipated to enter phase II clinical trials in 2017.
Three further molecules have been developed
in-house
from two proprietary drug discovery platforms (superbenzopyrans and anti-tropomyosins) to treat ovarian cancer and a range of solid tumours. Cantrixil, the
most advanced of these, commenced a
first-in-human
clinical study in patients with ovarian cancer in late 2016, while Anisina and Trilexium are in preclinical
development.
For more information, please visit:
www.novogen.com
|
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Apr 2024 to May 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From May 2023 to May 2024